Merck has announced the results that suggest combining its Keytruda therapy with chemotherapy extends the overall survival and progression-free survival for lung cancer patients. Credit: John Campbell via Flickr.

Merck has announced the results from its Phase 3 Keynote-407 trial that suggest combining its Keytruda therapy with carboplatin-paclitaxel or nab-paclitaxel chemotherapy extends the primary end points of overall survival and progression-free survival for lung cancer patients, compared with treatment with chemotherapy alone.

The Keynote-407 trial is a randomised, double-blind, placebo-controlled study of 560 untreated patients with metastatic squamous non-small cell lung cancer (NSCLC), the most common form of lung cancer.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Keytruda is a humanised monoclonal antibody that improves the ability of the body’s immune system to help detect and fight tumour cells.

It is called an anti-PD-1 therapy because it works by blocking the interaction between programmed cell death protein 1 (PD-1), a cell surface receptor that contributes to down-regulating the immune system and suppressing T cell inflammatory activity, and programmed death-ligand 1 (PD-L1) and programmed death-ligand 2 (PD-L2), which suppress the immune system and inhibit the activation of T lymphocytes to combat cancerous cells.

The trial is one of the more than 750 trials Merck is undertaking to study Keytruda’s effectiveness across cancer and treatment settings.

Merck Research Laboratories president Dr Roger M Perlmutter said: “As first-line treatment, Keytruda in combination with traditional chemotherapy has now demonstrated an improved survival benefit, compared to chemotherapy alone, in metastatic lung cancer patients with squamous histology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We look forward to presenting the overall survival and progression-free survival findings from Keynote-407 at the 2018 ASCO Annual Meeting, and are grateful to the patients and investigators for their important contributions to this pivotal study.”

The company has already submitted its Biologics Licence Application to the US Food and Drug Administration, but this new data will be shared with the organisation.